151
|
Li S, Zhao J, Guo Y, Mei Y, Yuan B, Gan N, Zhang J, Hu J, Hou H. Influence of the introduction of a triphenylphosphine group on the anticancer activity of a copper complex. J Inorg Biochem 2020; 210:111102. [PMID: 32574870 DOI: 10.1016/j.jinorgbio.2020.111102] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Revised: 04/29/2020] [Accepted: 04/30/2020] [Indexed: 12/20/2022]
Abstract
Aiming at obtaining new copper complexes with good cytotoxicity against cancer cells, triphenylphosphine (TPP) was introduced to obtain insight into the influence of the co-ligands. In this paper, two copper complexes, Cu(2-pbmq)(CH3OH)Br2 (1) and [Cu(2-pbmq)(TPP)Br]2 (2) were designed, synthesized, and characterized by X-ray crystallography, 2-((2-(pyrazin-2-yl)-1H-benzo[d]imidazol-1-yl)methyl))quinolone (2-pbmq), to investigate the influence of the TPP group on the anticancer activity of the metal complex. Although the presence of the TPP group diminished the intensity of the interaction properties of the complex with DNA, the in vitro anticancer activity and cellular uptake of the TPP-containing complex were markedly superior to those of its TPP-lacking counterpart. Detailed studies on the more potently cytotoxic complex 2 revealed that it accumulated in nucleus, arrested the cell cycle at the G0-G1 phase, causing mitochondrial dysfunction, involving the potential simultaneous mitochondrial membrane collapse, cellular ATP level depletion, and Ca2+ leakage, eventually inducing cell apoptosis. In summary, the introduction of a TPP group enhances the biological activity and cytotoxicity of the complex.
Collapse
Affiliation(s)
- Sen Li
- College of Chemistry, Zhengzhou University, Zhengzhou 450001, Henan, PR China
| | - Jin'an Zhao
- College of Material and Chemical Engineering, Henan University of Urban Construction, Pingdingshan 467036, Henan, PR China.
| | - Yan Guo
- College of Material and Chemical Engineering, Henan University of Urban Construction, Pingdingshan 467036, Henan, PR China
| | - Yameng Mei
- College of Chemistry, Zhengzhou University, Zhengzhou 450001, Henan, PR China
| | - Bangpeng Yuan
- College of Chemistry, Zhengzhou University, Zhengzhou 450001, Henan, PR China
| | - Ning Gan
- College of Material and Chemical Engineering, Henan University of Urban Construction, Pingdingshan 467036, Henan, PR China
| | - Junshuai Zhang
- College of Material and Chemical Engineering, Henan University of Urban Construction, Pingdingshan 467036, Henan, PR China
| | - Jiyong Hu
- College of Material and Chemical Engineering, Henan University of Urban Construction, Pingdingshan 467036, Henan, PR China.
| | - Hongwei Hou
- College of Chemistry, Zhengzhou University, Zhengzhou 450001, Henan, PR China
| |
Collapse
|
152
|
George SL, Parmar V, Lorenzi F, Marshall LV, Jamin Y, Poon E, Angelini P, Chesler L. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma. J Exp Clin Cancer Res 2020; 39:78. [PMID: 32375866 PMCID: PMC7201617 DOI: 10.1186/s13046-020-01582-2] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2020] [Accepted: 04/22/2020] [Indexed: 12/13/2022] Open
Abstract
The majority of high-risk neuroblastomas can be divided into three distinct molecular subgroups defined by the presence of MYCN amplification, upstream TERT rearrangements or alternative lengthening of telomeres (ALT). The common defining feature of all three subgroups is altered telomere maintenance; MYCN amplification and upstream TERT rearrangements drive high levels of telomerase expression whereas ALT is a telomerase independent telomere maintenance mechanism. As all three telomere maintenance mechanisms are independently associated with poor outcomes, the development of strategies to selectively target either telomerase expressing or ALT cells holds great promise as a therapeutic approach that is applicable to the majority of children with aggressive disease.Here we summarise the biology of telomere maintenance and the molecular drivers of aggressive neuroblastoma before describing the most promising therapeutic strategies to target both telomerase expressing and ALT cancers. For telomerase-expressing neuroblastoma the most promising targeted agent to date is 6-thio-2'-deoxyguanosine, however clinical development of this agent is required. In osteosarcoma cell lines with ALT, selective sensitivity to ATR inhibition has been reported. However, we present data showing that in fact ALT neuroblastoma cells are more resistant to the clinical ATR inhibitor AZD6738 compared to other neuroblastoma subtypes. More recently a number of additional candidate compounds have been shown to show selectivity for ALT cancers, such as Tetra-Pt (bpy), a compound targeting the telomeric G-quadruplex and pifithrin-α, a putative p53 inhibitor. Further pre-clinical evaluation of these compounds in neuroblastoma models is warranted.In summary, telomere maintenance targeting strategies offer a significant opportunity to develop effective new therapies, applicable to a large proportion of children with high-risk neuroblastoma. In parallel to clinical development, more pre-clinical research specifically for neuroblastoma is urgently needed, if we are to improve survival for this common poor outcome tumour of childhood.
Collapse
Affiliation(s)
- S L George
- Paediatric Tumour Biology, Division of Clinical Studies, The Institute of Cancer Research, London, UK.
- Children and Young People's Unit, Royal Marsden NHS Foundation Trust, London, UK.
| | - V Parmar
- Children and Young People's Unit, Royal Marsden NHS Foundation Trust, London, UK
| | - F Lorenzi
- Paediatric Tumour Biology, Division of Clinical Studies, The Institute of Cancer Research, London, UK
| | - L V Marshall
- Paediatric Tumour Biology, Division of Clinical Studies, The Institute of Cancer Research, London, UK
- Children and Young People's Unit, Royal Marsden NHS Foundation Trust, London, UK
| | - Y Jamin
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
| | - E Poon
- Paediatric Tumour Biology, Division of Clinical Studies, The Institute of Cancer Research, London, UK
| | - P Angelini
- Children and Young People's Unit, Royal Marsden NHS Foundation Trust, London, UK
| | - L Chesler
- Paediatric Tumour Biology, Division of Clinical Studies, The Institute of Cancer Research, London, UK
- Children and Young People's Unit, Royal Marsden NHS Foundation Trust, London, UK
| |
Collapse
|
153
|
Kim SM, Kang OY, Lim HJ, Park SJ. Selective Synthesis of N-Cyano Sulfilimines by Dearomatizing Stable Thionium Ions. ACS OMEGA 2020; 5:10191-10199. [PMID: 32391507 PMCID: PMC7203956 DOI: 10.1021/acsomega.0c01086] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Accepted: 04/09/2020] [Indexed: 05/28/2023]
Abstract
For the selective synthesis of N-cyano sulfilimines, we have developed a new method based on the soft-soft interaction between thionium ion electrophiles and cyanonitrene nucleophiles. The stable thionium ion was successfully obtained by oxidative dearomatization using phenyliodine (III) diacetate (PIDA) in N,N-dimethylformamide (DMF). The sulfur imination reactions were tolerant to a wide range of functional groups and exhibited high selectivities and excellent yields. The existence of thionium ion intermediates was confirmed by ultraviolet/visible (UV/vis) spectroscopy and 1H NMR experiments.
Collapse
Affiliation(s)
- Sang Mee Kim
- Department
of Drug Discovery, Korea Research Institute
of Chemical Technology, 141 Gajeong-ro, Daejeon 34114, Republic of Korea
- Department
of Chemistry, Sogang University, 35 Baekbeom-ro, Mapo-gu, Seoul 04107, Republic
of Korea
| | - On-Yu Kang
- Department
of Drug Discovery, Korea Research Institute
of Chemical Technology, 141 Gajeong-ro, Daejeon 34114, Republic of Korea
- Department
of Chemistry, Sungkyunkwan University, 2066 Seobu-ro, Suwon 16419, Republic
of Korea
| | - Hwan Jung Lim
- Department
of Drug Discovery, Korea Research Institute
of Chemical Technology, 141 Gajeong-ro, Daejeon 34114, Republic of Korea
- Department
of Medicinal and Pharmaceutical Chemistry, University of Science & Technology, 217 Gajeong-ro, Daejeon 34113, Republic of Korea
| | - Seong Jun Park
- Department
of Drug Discovery, Korea Research Institute
of Chemical Technology, 141 Gajeong-ro, Daejeon 34114, Republic of Korea
| |
Collapse
|
154
|
Dibitetto D, Sims JR, Ascenção CFR, Feng K, Kim D, Oberly S, Freire R, Smolka MB. Intrinsic ATR signaling shapes DNA end resection and suppresses toxic DNA-PKcs signaling. NAR Cancer 2020; 2:zcaa006. [PMID: 32743550 PMCID: PMC7380482 DOI: 10.1093/narcan/zcaa006] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 04/08/2020] [Accepted: 04/16/2020] [Indexed: 12/13/2022] Open
Abstract
Most cancer cells experience oncogene-induced replication stress and, as a result, exhibit high intrinsic activation of the ATR kinase. Although cancer cells often become more dependent on ATR for survival, the precise mechanism by which ATR signaling ensures cancer cell fitness and viability remains incompletely understood. Here, we find that intrinsic ATR signaling is crucial for the ability of cancer cells to promote DNA end resection, the first step in homology-directed DNA repair. Inhibition of ATR over multiple cell division cycles depletes the pool of pro-resection factors and prevents the engagement of RAD51 as well as RAD52 at nuclear foci, leading to toxic DNA-PKcs signaling and hypersensitivity to PARP inhibitors. The effect is markedly distinct from acute ATR inhibition, which blocks RAD51-mediated repair but not resection and engagement of RAD52. Our findings reveal a key pro-resection function for ATR and define how ATR inhibitors can be used for effective manipulation of DNA end resection capacity and DNA repair outcomes in cancer cells.
Collapse
Affiliation(s)
- Diego Dibitetto
- Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, USA
| | - Jennie R Sims
- Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, USA
| | - Carolline F R Ascenção
- Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, USA
| | - Kevin Feng
- Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, USA
| | - Dongsung Kim
- Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, USA
| | - Susannah Oberly
- Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, USA
| | - Raimundo Freire
- Unidad de Investigación, Hospital Universitario de Canarias, Ofra s/n, La Cuesta, 38320 La Laguna, Tenerife, Spain.,Instituto de Tecnologías Biomédicas, Universidad de La Laguna, 38200 La Laguna, Tenerife, Spain.,Universidad Fernando Pessoa Canarias, 35450 Las Palmas de Gran Canaria, Spain
| | - Marcus B Smolka
- Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, USA
| |
Collapse
|
155
|
Krauskopf F, Truong K, Rissanen K, Bolm C. [3+2]‐Cycloadditions of
N
‐Cyano Sulfoximines with 1,3‐Dipoles. European J Org Chem 2020. [DOI: 10.1002/ejoc.202000335] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Felix Krauskopf
- Institute of Organic Chemistry RWTH Aachen University Landoltweg 1 52074 Aachen Germany
| | - Khai‐Nghi Truong
- Department of Chemistry University of Jyvaskyla P.O. Box. 35, Survontie 9 B 40014 Jyväskylä Finland
| | - Kari Rissanen
- Department of Chemistry University of Jyvaskyla P.O. Box. 35, Survontie 9 B 40014 Jyväskylä Finland
| | - Carsten Bolm
- Institute of Organic Chemistry RWTH Aachen University Landoltweg 1 52074 Aachen Germany
| |
Collapse
|
156
|
Mendonça Matos P, Lewis W, Argent SP, Moore JC, Stockman RA. General Method for the Asymmetric Synthesis of N-H Sulfoximines via C-S Bond Formation. Org Lett 2020; 22:2776-2780. [PMID: 32176512 DOI: 10.1021/acs.orglett.0c00761] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
A versatile method for the synthesis of enantioenriched N-H sulfoximines is reported. The approach stems from the organomagnesium-mediated ring opening of novel cyclic sulfonimidate templates. The reactions proceed in high yield and with excellent stereofidelity with alkyl, aryl, and heteroaryl Grignard reagents. The chiral auxiliary is readily removed from the resultant sulfoximines via an unusual oxidative debenzylation protocol that utilizes molecular oxygen as the terminal oxidant. This provides a general strategy for the synthesis of highly enantioenriched N-H sulfoximines.
Collapse
Affiliation(s)
- Priscilla Mendonça Matos
- Department of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD, U.K.,CAPES Foundation, Ministry of Education of Brazil, Brasília, DF 70040-020, Brazil
| | - William Lewis
- Department of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD, U.K
| | - Stephen P Argent
- Department of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD, U.K
| | - Jonathan C Moore
- Department of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD, U.K
| | - Robert A Stockman
- Department of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD, U.K
| |
Collapse
|
157
|
Boulard E, Zibulski V, Oertel L, Lienau P, Schäfer M, Ganzer U, Lücking U. Increasing Complexity: A Practical Synthetic Approach to Three-Dimensional, Cyclic Sulfoximines and First Insights into Their in Vitro Properties. Chemistry 2020; 26:4378-4388. [PMID: 31961028 DOI: 10.1002/chem.201905461] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 01/17/2020] [Indexed: 12/13/2022]
Abstract
A short synthetic approach with broad scope to access five- to seven-membered cyclic sulfoximines in only two to three steps from readily available thiophenols is reported. Thus, simple building blocks were converted to complex molecular structures by a sequence of S-alkylation and one-pot sulfoximine formation, followed by intramolecular cyclization. Seventeen structurally diverse cyclic sulfoximines were prepared in high overall yields. In vitro evaluation of these underrepresented, three-dimensional, cyclic sulfoximines with respect to properties relevant to medicinal chemistry did not reveal any intrinsic flaw for application in drug discovery.
Collapse
Affiliation(s)
- Emilie Boulard
- Bâtiment Hubert Curien 43, CPE Lyon-Campus LyonTech/la Doua, boulevard du 11 Novembre 1918, 69616, Villeurbanne Cedex, France
| | - Vivien Zibulski
- Pharmaceuticals Division, Drug Discovery Department, Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany
| | - Luisa Oertel
- Pharmaceuticals Division, Drug Discovery Department, Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany
| | - Philip Lienau
- Pharmaceuticals Division, Drug Discovery Department, Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany
| | - Martina Schäfer
- Pharmaceuticals Division, Drug Discovery Department, Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany
| | - Ursula Ganzer
- Pharmaceuticals Division, Drug Discovery Department, Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany
| | - Ulrich Lücking
- Pharmaceuticals Division, Drug Discovery Department, Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany
| |
Collapse
|
158
|
Zhang G, Tan H, Chen W, Shen HC, Lu Y, Zheng C, Xu H. Synthesis of NH-Sulfoximines by Using Recyclable Hypervalent Iodine(III) Reagents under Aqueous Micellar Conditions. CHEMSUSCHEM 2020; 13:922-928. [PMID: 31950602 DOI: 10.1002/cssc.201903430] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Revised: 01/17/2020] [Indexed: 05/28/2023]
Abstract
The synthesis of NH-sulfoximines from sulfides has been first developed under mild conditions in an aqueous solution with surfactant TPGS-750-M as the catalyst at room temperature. In this newly developed process, a simple and convenient recycling strategy to regenerate the indispensable hypervalent iodine(III) is used. The resulting 1,2,3-trifluoro-5-iodobezene can be recovered almost quantitively from the mixture by liquid-liquid extraction and then oxidized to give the corresponding iodine(III) species. This optimized procedure is compatible with a broad range of functional groups and can be easily performed on a gram scale, providing a green protocol for the synthesis of sulfoximines.
Collapse
Affiliation(s)
- Guocai Zhang
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China
- Roche Innovation Center Shanghai, Roche Pharma Research and Early Development, 720 Cai Lun Road, Shanghai, 201203, P. R. China
| | - Hongsheng Tan
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China
| | - Weichun Chen
- Roche Innovation Center Shanghai, Roche Pharma Research and Early Development, 720 Cai Lun Road, Shanghai, 201203, P. R. China
| | - Hong C Shen
- Roche Innovation Center Shanghai, Roche Pharma Research and Early Development, 720 Cai Lun Road, Shanghai, 201203, P. R. China
| | - Yue Lu
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China
| | - Changwu Zheng
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China
| | - Hongxi Xu
- Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China
| |
Collapse
|
159
|
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations? Pharmacol Ther 2020; 207:107450. [DOI: 10.1016/j.pharmthera.2019.107450] [Citation(s) in RCA: 54] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Accepted: 11/22/2019] [Indexed: 12/22/2022]
|
160
|
Gorecki L, Andrs M, Rezacova M, Korabecny J. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy. Pharmacol Ther 2020; 210:107518. [PMID: 32109490 DOI: 10.1016/j.pharmthera.2020.107518] [Citation(s) in RCA: 56] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Accepted: 02/11/2020] [Indexed: 02/07/2023]
Abstract
Chemoresistance, radioresistance, and the challenge of achieving complete resection are major driving forces in the search for more robust and targeted anticancer therapies. Targeting the DNA damage response has recently attracted research interest, as these processes are enhanced in tumour cells. The major replication stress responder is ATM and Rad3-related (ATR) kinase, which is attracting attention worldwide with four drug candidates currently in phase I/II clinical trials. This review addresses a potent and selective small-molecule ATR inhibitor, which is known as VX-970 (also known as berzosertib or M6620), and summarizes the existing preclinical data to provide deep insight regarding its real potential. We also outline the transition from preclinical to clinical studies, as well as its relationships with other clinical candidates (AZD6738, VX-803 [M4344], and BAY1895344). The results suggest that VX-970 is indeed a promising anticancer drug that can be used both as monotherapy and in combination with either chemotherapy or radiotherapy strategies. Based on patient anamnesis and biomarker identification, VX-970 could become a valuable tool for oncologists in the fight against cancer.
Collapse
Affiliation(s)
- Lukas Gorecki
- Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
| | - Martin Andrs
- Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic; Laboratory of Cancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic
| | - Martina Rezacova
- Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 38 Hradec Kralove, Czech Republic
| | - Jan Korabecny
- Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic.
| |
Collapse
|
161
|
Brunner AM, Steensma DP. Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity. Hematol Oncol Clin North Am 2020; 34:379-391. [PMID: 32089217 DOI: 10.1016/j.hoc.2019.10.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Myelodysplastic syndromes are enriched for somatic mutations in the pre-mRNA splicing apparatus, with recurrent acquired mutations most commonly occurring in SF3B1, SRSF2, U2AF1, and ZRSR2. These mutations appear to be early events in the pathogenesis of disease, and, given their frequency and central role in leukemogenesis, are of interest as potential therapeutic targets. Clinical trials are exploring targets that directly affect the spliceosome (splicing modulators or protein arginine methyltransferase 5 inhibitors) or that exploit possible vulnerabilities created by alternative splicing (inhibiting ATR). Future research is needed to explore novel targets and therapeutic combinations and understand how these mutations lead to clonal dominance.
Collapse
Affiliation(s)
- Andrew M Brunner
- Massachusetts General Hospital, Zero Emerson Place, Suite 118, Boston, MA 02114, USA.
| | - David P Steensma
- Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
| |
Collapse
|
162
|
Abstract
Cancer is a multi-step process during which cells acquire mutations that eventually lead to uncontrolled cell growth and division and evasion of programmed cell death. The oncogenes such as Ras and c-Myc may be responsible in all three major stages of cancer i.e., early, intermediate, and late. The NF-κB has been shown to control the expression of genes linked with tumor pathways such as chronic inflammation, tumor cell survival, anti-apoptosis, proliferation, invasion, and angiogenesis. In the last few decades, various biomarker pathways have been identified that play a critical role in carcinogenesis such as Ras, NF-κB and DNA damage.
Collapse
Affiliation(s)
- Anas Ahmad
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India.,Department of Nano-Therapeutics, Institute of Nano Science and Technology (INST), Habitat Centre, Mohali, India
| | - Haseeb Ahsan
- Department of Biochemistry, Faculty of Dentistry, Jamia Millia Islamia (A Central University), New Delhi, India
| |
Collapse
|
163
|
Schumacher C, Fergen H, Puttreddy R, Truong KN, Rinesch T, Rissanen K, Bolm C. N-(2,3,5,6-Tetrafluoropyridyl)sulfoximines: synthesis, X-ray crystallography, and halogen bonding. Org Chem Front 2020. [DOI: 10.1039/d0qo01139h] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
N-(Tetrafluoropyridyl)sulfoximines are obtained from NH-sulfoximines and pentafluoropyridine under solution-based or mechanochemical conditions, and the solid-state structures of 26 products have been determined by X-ray diffraction analysis.
Collapse
Affiliation(s)
| | - Hannah Fergen
- Institute of Organic Chemistry
- RWTH Aachen University
- 52074 Aachen
- Germany
| | - Rakesh Puttreddy
- Institute of Organic Chemistry
- RWTH Aachen University
- 52074 Aachen
- Germany
- University of Jyvaskyla
| | - Khai-Nghi Truong
- University of Jyvaskyla
- Department of Chemistry
- FI-40014 Jyväskylä
- Finland
| | - Torsten Rinesch
- Institute of Organic Chemistry
- RWTH Aachen University
- 52074 Aachen
- Germany
| | - Kari Rissanen
- University of Jyvaskyla
- Department of Chemistry
- FI-40014 Jyväskylä
- Finland
| | - Carsten Bolm
- Institute of Organic Chemistry
- RWTH Aachen University
- 52074 Aachen
- Germany
| |
Collapse
|
164
|
Cussiol JRR, Soares BL, Oliveira FMBD. From yeast to humans: Understanding the biology of DNA Damage Response (DDR) kinases. Genet Mol Biol 2019; 43:e20190071. [PMID: 31930279 PMCID: PMC7198005 DOI: 10.1590/1678-4685-gmb-2019-0071] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2019] [Accepted: 07/19/2019] [Indexed: 12/20/2022] Open
Abstract
The DNA Damage Response (DDR) is a complex network of biological processes that protect cells from accumulating aberrant DNA structures, thereby maintaining genomic stability and, as a consequence, preventing the development of cancer and other diseases. The DDR pathway is coordinated by a signaling cascade mediated by the PI3K-like kinases (PIKK) ATM and ATR and by their downstream kinases CHK2 and CHK1, respectively. Together, these kinases regulate several aspects of the cellular program in response to genomic stress. Much of our understanding of these kinases came from studies performed in the 1990s using yeast as a model organism. The purpose of this review is to present a historical perspective on the discovery of the DDR kinases in yeast and the importance of this model for the identification and functional understanding of their mammalian orthologues.
Collapse
Affiliation(s)
| | - Bárbara Luísa Soares
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | | |
Collapse
|
165
|
Pouliot GP, Degar J, Hinze L, Kochupurakkal B, Vo CD, Burns MA, Moreau L, Ganesa C, Roderick J, Peirs S, Menten B, Loh ML, Hunger SP, Silverman LB, Harris MH, Stevenson KE, Weinstock DM, Weng AP, Van Vlierberghe P, D’Andrea AD, Gutierrez A. Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. PLoS One 2019; 14:e0221288. [PMID: 31721781 PMCID: PMC6853288 DOI: 10.1371/journal.pone.0221288] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Accepted: 08/02/2019] [Indexed: 01/03/2023] Open
Abstract
BRCA2 (also known as FANCD1) is a core component of the Fanconi pathway and suppresses transformation of immature T-cells in mice. However, the contribution of Fanconi-BRCA pathway deficiency to human T-cell acute lymphoblastic leukemia (T-ALL) remains undefined. We identified point mutations in 9 (23%) of 40 human T-ALL cases analyzed, with variant allele fractions consistent with heterozygous mutations early in tumor evolution. Two of these mutations were present in remission bone marrow specimens, suggesting germline alterations. BRCA2 was the most commonly mutated gene. The identified Fanconi-BRCA mutations encode hypomorphic or null alleles, as evidenced by their inability to fully rescue Fanconi-deficient cells from chromosome breakage, cytotoxicity and/or G2/M arrest upon treatment with DNA cross-linking agents. Disabling the tumor suppressor activity of the Fanconi-BRCA pathway is generally thought to require biallelic gene mutations. However, all mutations identified were monoallelic, and most cases appeared to retain expression of the wild-type allele. Using isogenic T-ALL cells, we found that BRCA2 haploinsufficiency induces selective hypersensitivity to ATR inhibition, in vitro and in vivo. These findings implicate Fanconi-BRCA pathway haploinsufficiency in the molecular pathogenesis of T-ALL, and provide a therapeutic rationale for inhibition of ATR or other druggable effectors of homologous recombination.
Collapse
Affiliation(s)
- Gayle P. Pouliot
- Division of Hematology/Oncology, Boston Children’s Hospital, Boston, Massachusetts, United States of America
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
| | - James Degar
- Division of Hematology/Oncology, Boston Children’s Hospital, Boston, Massachusetts, United States of America
| | - Laura Hinze
- Division of Hematology/Oncology, Boston Children’s Hospital, Boston, Massachusetts, United States of America
| | - Bose Kochupurakkal
- Center for DNA Damage and Repair and Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
| | - Chau D. Vo
- Division of Hematology/Oncology, Boston Children’s Hospital, Boston, Massachusetts, United States of America
| | - Melissa A. Burns
- Division of Hematology/Oncology, Boston Children’s Hospital, Boston, Massachusetts, United States of America
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
| | - Lisa Moreau
- Division of Hematology/Oncology, Boston Children’s Hospital, Boston, Massachusetts, United States of America
- Center for DNA Damage and Repair and Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
| | - Chirag Ganesa
- Center for DNA Damage and Repair and Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
| | - Justine Roderick
- Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
| | - Sofie Peirs
- Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
| | - Bjorn Menten
- Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
| | - Mignon L. Loh
- Department of Pediatrics, University of California San Francisco, San Francisco, California, United States of America
| | - Stephen P. Hunger
- Division of Oncology and the Center for Childhood Cancer Research, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America
| | - Lewis B. Silverman
- Division of Hematology/Oncology, Boston Children’s Hospital, Boston, Massachusetts, United States of America
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
| | - Marian H. Harris
- Department of Pathology, Boston Children’s Hospital, Boston, Massachusetts, United States of America
| | - Kristen E. Stevenson
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
| | - David M. Weinstock
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
| | - Andrew P. Weng
- Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | | | - Alan D. D’Andrea
- Division of Hematology/Oncology, Boston Children’s Hospital, Boston, Massachusetts, United States of America
- Center for DNA Damage and Repair and Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
| | - Alejandro Gutierrez
- Division of Hematology/Oncology, Boston Children’s Hospital, Boston, Massachusetts, United States of America
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
- * E-mail:
| |
Collapse
|
166
|
Wengner AM, Siemeister G, Lücking U, Lefranc J, Wortmann L, Lienau P, Bader B, Bömer U, Moosmayer D, Eberspächer U, Golfier S, Schatz CA, Baumgart SJ, Haendler B, Lejeune P, Schlicker A, von Nussbaum F, Brands M, Ziegelbauer K, Mumberg D. The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models. Mol Cancer Ther 2019; 19:26-38. [PMID: 31582533 DOI: 10.1158/1535-7163.mct-19-0019] [Citation(s) in RCA: 116] [Impact Index Per Article: 23.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Revised: 07/05/2019] [Accepted: 09/27/2019] [Indexed: 11/16/2022]
Abstract
The DNA damage response (DDR) secures the integrity of the genome of eukaryotic cells. DDR deficiencies can promote tumorigenesis but concurrently may increase dependence on alternative repair pathways. The ataxia telangiectasia and Rad3-related (ATR) kinase plays a central role in the DDR by activating essential signaling pathways of DNA damage repair. Here, we studied the effect of the novel selective ATR kinase inhibitor BAY 1895344 on tumor cell growth and viability. Potent antiproliferative activity was demonstrated in a broad spectrum of human tumor cell lines. BAY 1895344 exhibited strong monotherapy efficacy in cancer xenograft models that carry DNA damage repair deficiencies. The combination of BAY 1895344 with DNA damage-inducing chemotherapy or external beam radiotherapy (EBRT) showed synergistic antitumor activity. Combination treatment with BAY 1895344 and DDR inhibitors achieved strong synergistic antiproliferative activity in vitro, and combined inhibition of ATR and PARP signaling using olaparib demonstrated synergistic antitumor activity in vivo Furthermore, the combination of BAY 1895344 with the novel, nonsteroidal androgen receptor antagonist darolutamide resulted in significantly improved antitumor efficacy compared with respective single-agent treatments in hormone-dependent prostate cancer, and addition of EBRT resulted in even further enhanced antitumor efficacy. Thus, the ATR inhibitor BAY 1895344 may provide new therapeutic options for the treatment of cancers with certain DDR deficiencies in monotherapy and in combination with DNA damage-inducing or DNA repair-compromising cancer therapies by improving their efficacy.
Collapse
Affiliation(s)
- Antje M Wengner
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
| | | | - Ulrich Lücking
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Julien Lefranc
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Lars Wortmann
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Philip Lienau
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Benjamin Bader
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Ulf Bömer
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Dieter Moosmayer
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Uwe Eberspächer
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Sven Golfier
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | | | - Simon J Baumgart
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Bernard Haendler
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Pascale Lejeune
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Andreas Schlicker
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | | | - Michael Brands
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Karl Ziegelbauer
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Dominik Mumberg
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| |
Collapse
|
167
|
Hande S, Mfuh A, Throner S, Wu Y, Ye Q, Zheng X. Photoredox mediated C N cross coupling of sulfoximines with aryl iodides. Tetrahedron Lett 2019. [DOI: 10.1016/j.tetlet.2019.151100] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
168
|
Brosge F, Lorenz T, Helten H, Bolm C. BN- and BO-Doped Inorganic-Organic Hybrid Polymers with Sulfoximine Core Units. Chemistry 2019; 25:12708-12711. [PMID: 31433083 PMCID: PMC6790941 DOI: 10.1002/chem.201903289] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Revised: 08/20/2019] [Indexed: 01/19/2023]
Abstract
While polysulfones constitute a class of well-established, highly valuable applied materials, knowledge about polymers based on the related sulfoximine group is very limited. We have employed functionalized diaryl sulfoximines and a p-phenylene bisborane as building blocks for unprecedented BN- and BO-doped alternating inorganic-organic hybrid copolymers. While the former were accessed by a facile silicon/boron exchange protocol, the synthesis of polymers with main-chain B-O linkages was achieved by salt elimination.
Collapse
Affiliation(s)
- Felix Brosge
- Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074, Aachen, Germany
| | - Thomas Lorenz
- Institute of Inorganic Chemistry, RWTH Aachen University, Landoltweg 1, 52074, Aachen, Germany.,Institute of Inorganic Chemistry, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074, Würzburg, Germany
| | - Holger Helten
- Institute of Inorganic Chemistry, RWTH Aachen University, Landoltweg 1, 52074, Aachen, Germany.,Institute of Inorganic Chemistry, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074, Würzburg, Germany
| | - Carsten Bolm
- Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074, Aachen, Germany
| |
Collapse
|
169
|
Ivy SP, Kunos CA, Arnaldez FI, Kohn EC. Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints. Expert Opin Investig Drugs 2019; 28:771-785. [PMID: 31449760 DOI: 10.1080/13543784.2019.1657403] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Introduction: Molecular analyzes including molecular descriptor/phenotype interactions have led to better characterization of epithelial ovarian cancer patients, including a definition of a BRCA wild-type (BRCAwt) phenotype. Understanding how and when to use agents targeted against dependent BRCAwt pathways or other molecular events at disease progression is an important translational and therapeutic direction in ovarian cancer research. Areas covered: In this overview, we provide definitions and descriptions of a BRCAwt genotype and phenotype. We discuss novel investigational drugs that hold promise for the treatment of BRCAwt ovarian cancer, including inhibitors of poly(ADP-ribose) polymerase, ribonucleotide reductase, DNA protein kinase-catalytic subunit, ataxia-telangiectasia-mutated kinase (ATM), ataxia-telangiectasia mutated and Rad3-related kinase (ATR), CHK 1/2, cyclin kinases, glutaminase-1, WEE1 kinase, as well as tumor microenvironment and angiogenesis inhibitors. This article explores the known and the emerging areas of clinical research on patients with BRCAwt ovarian cancer. Expert opinion: Discovery of molecular changes tied to annotated disease information, along with an expanding array of pathway targets and targeted therapeutic agents, creates optimism and opportunity for women with ovarian cancer. Using precision oncology approaches, clinical researchers are, and will be, poised to select more effective treatments for ovarian cancer patients.
Collapse
Affiliation(s)
- S Percy Ivy
- Cancer Therapy Evaluation Program, National Cancer Institute (NCI) , Bethesda , MD , USA
| | - Charles A Kunos
- Cancer Therapy Evaluation Program, National Cancer Institute (NCI) , Bethesda , MD , USA
| | - Fernanda I Arnaldez
- Cancer Therapy Evaluation Program, National Cancer Institute (NCI) , Bethesda , MD , USA
| | - Elise C Kohn
- Cancer Therapy Evaluation Program, National Cancer Institute (NCI) , Bethesda , MD , USA
| |
Collapse
|
170
|
Briggs EL, Tota A, Colella M, Degennaro L, Luisi R, Bull JA. Synthesis of Sulfonimidamides from Sulfenamides via an Alkoxy‐amino‐λ
6
‐sulfanenitrile Intermediate. Angew Chem Int Ed Engl 2019; 58:14303-14310. [DOI: 10.1002/anie.201906001] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Revised: 07/26/2019] [Indexed: 11/06/2022]
Affiliation(s)
- Edward L. Briggs
- Department of Chemistry Imperial College London Molecular Sciences Research Hub White City Campus Wood Lane W12 0BZ UK
| | - Arianna Tota
- Department of Pharmacy-Drug Sciences University of Bari “A. Moro” Via E. Orabona 4 Bari 70125 Italy
| | - Marco Colella
- Department of Pharmacy-Drug Sciences University of Bari “A. Moro” Via E. Orabona 4 Bari 70125 Italy
| | - Leonardo Degennaro
- Department of Pharmacy-Drug Sciences University of Bari “A. Moro” Via E. Orabona 4 Bari 70125 Italy
| | - Renzo Luisi
- Department of Pharmacy-Drug Sciences University of Bari “A. Moro” Via E. Orabona 4 Bari 70125 Italy
| | - James A. Bull
- Department of Chemistry Imperial College London Molecular Sciences Research Hub White City Campus Wood Lane W12 0BZ UK
| |
Collapse
|
171
|
Briggs EL, Tota A, Colella M, Degennaro L, Luisi R, Bull JA. Synthesis of Sulfonimidamides from Sulfenamides via an Alkoxy‐amino‐λ
6
‐sulfanenitrile Intermediate. Angew Chem Int Ed Engl 2019. [DOI: 10.1002/ange.201906001] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Edward L. Briggs
- Department of Chemistry Imperial College London Molecular Sciences Research Hub White City Campus Wood Lane W12 0BZ UK
| | - Arianna Tota
- Department of Pharmacy-Drug Sciences University of Bari “A. Moro” Via E. Orabona 4 Bari 70125 Italy
| | - Marco Colella
- Department of Pharmacy-Drug Sciences University of Bari “A. Moro” Via E. Orabona 4 Bari 70125 Italy
| | - Leonardo Degennaro
- Department of Pharmacy-Drug Sciences University of Bari “A. Moro” Via E. Orabona 4 Bari 70125 Italy
| | - Renzo Luisi
- Department of Pharmacy-Drug Sciences University of Bari “A. Moro” Via E. Orabona 4 Bari 70125 Italy
| | - James A. Bull
- Department of Chemistry Imperial College London Molecular Sciences Research Hub White City Campus Wood Lane W12 0BZ UK
| |
Collapse
|
172
|
Brauns M, Cramer N. Efficient Kinetic Resolution of Sulfur‐Stereogenic Sulfoximines by Exploiting Cp
X
Rh
III
‐Catalyzed C−H Functionalization. Angew Chem Int Ed Engl 2019; 58:8902-8906. [DOI: 10.1002/anie.201904543] [Citation(s) in RCA: 88] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Indexed: 11/06/2022]
Affiliation(s)
- Marcus Brauns
- Laboratory of Asymmetric Catalysis and SynthesisEPFL SB ISIC LCSA, BCH 4305 1015 Lausanne Switzerland
| | - Nicolai Cramer
- Laboratory of Asymmetric Catalysis and SynthesisEPFL SB ISIC LCSA, BCH 4305 1015 Lausanne Switzerland
| |
Collapse
|
173
|
Goundry WRF, Dai K, Gonzalez M, Legg D, O’Kearney-McMullan A, Morrison J, Stark A, Siedlecki P, Tomlin P, Yang J. Development and Scale-up of a Route to ATR Inhibitor AZD6738. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.9b00075] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- William R. F. Goundry
- Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Macclesfield SK102NA, United Kingdom
| | - Kuangchu Dai
- Changzhou SynTheAll Pharmaceutical Co. Ltd, No 589, North Yulong Road, Chunjiang Town, Xinbei
District, Changzhou 213127, Jiangsu P. R. China
| | - Miguel Gonzalez
- Asymchem Laboratories (Tianjin) Co. Ltd, No. 6 Dongting, Third Avenue, TEDA, Tianjin, 300457, P. R. China
| | - Daniel Legg
- Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Macclesfield SK102NA, United Kingdom
| | - Anne O’Kearney-McMullan
- Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield SK102NA, United Kingdom
| | - James Morrison
- Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Macclesfield SK102NA, United Kingdom
| | - Andrew Stark
- Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Macclesfield SK102NA, United Kingdom
| | - Paul Siedlecki
- Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield SK102NA, United Kingdom
| | - Paula Tomlin
- Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield SK102NA, United Kingdom
| | - Jianbo Yang
- Asymchem Laboratories (Tianjin) Co. Ltd, No. 6 Dongting, Third Avenue, TEDA, Tianjin, 300457, P. R. China
| |
Collapse
|
174
|
Leonard BC, Lee ED, Bhola NE, Li H, Sogaard KK, Bakkenist CJ, Grandis JR, Johnson DE. ATR inhibition sensitizes HPV - and HPV + head and neck squamous cell carcinoma to cisplatin. Oral Oncol 2019; 95:35-42. [PMID: 31345392 DOI: 10.1016/j.oraloncology.2019.05.028] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2019] [Revised: 05/21/2019] [Accepted: 05/29/2019] [Indexed: 01/01/2023]
Abstract
OBJECTIVES Cisplatin is commonly used in the treatment of head and neck squamous cell carcinoma (HNSCC), and the repair of cisplatin-induced DNA damage involves activation of the DNA damage response protein ataxia telangiectasia and Rad3-related (ATR). Resistance to cisplatin therapy exacerbates adverse toxicities and is associated with poor outcomes. Since repair of cisplatin-induced DNA damage contributes to resistance, we hypothesized that inhibition of ATR using AZD6738, a well-tolerated and orally-bioavailable inhibitor, would enhance the sensitivity of HNSCC cells and tumors to cisplatin. MATERIALS AND METHODS A panel of human papilloma virus-negative (HPV-) and HPV+ HNSCC cell lines were treated with cisplatin in the absence or presence of AZD6738, and effects on cell viability, colony formation, apoptosis signaling, and DNA damage were assessed. The impact of co-treatment with cisplatin plus AZD6738 on the growth of HPV- and HPV+ cell line- and patient-derived xenograft tumors was also examined. RESULTS Inhibition of ATR with AZD6738 enhanced cisplatin-induced growth inhibition of HNSCC cell lines and tumors, in association with increased apoptosis signaling and DNA damage. Both HPV- and HPV+ models were sensitized to cisplatin by ATR inhibition. CONCLUSION Inhibition of ATR promotes sensitization to cisplatin in preclinical in vitro and in vivo models of HPV- and HVP+ HNSCC, supporting clinical evaluation of this strategy in this disease.
Collapse
Affiliation(s)
- Brandon C Leonard
- Department of Otolaryngology, University of California, San Francisco, CA, USA
| | - Eliot D Lee
- Department of Otolaryngology, University of California, San Francisco, CA, USA
| | - Neil E Bhola
- Department of Otolaryngology, University of California, San Francisco, CA, USA
| | - Hua Li
- Department of Otolaryngology, University of California, San Francisco, CA, USA
| | - Kristian K Sogaard
- Department of Otolaryngology, University of California, San Francisco, CA, USA
| | - Christopher J Bakkenist
- Departments of Radiation Oncology and Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA
| | - Jennifer R Grandis
- Department of Otolaryngology, University of California, San Francisco, CA, USA
| | - Daniel E Johnson
- Department of Otolaryngology, University of California, San Francisco, CA, USA.
| |
Collapse
|
175
|
Brauns M, Cramer N. Efficient Kinetic Resolution of Sulfur‐Stereogenic Sulfoximines by Exploiting Cp
X
Rh
III
‐Catalyzed C−H Functionalization. Angew Chem Int Ed Engl 2019. [DOI: 10.1002/ange.201904543] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Marcus Brauns
- Laboratory of Asymmetric Catalysis and SynthesisEPFL SB ISIC LCSA, BCH 4305 1015 Lausanne Switzerland
| | - Nicolai Cramer
- Laboratory of Asymmetric Catalysis and SynthesisEPFL SB ISIC LCSA, BCH 4305 1015 Lausanne Switzerland
| |
Collapse
|
176
|
Young LA, O'Connor LO, de Renty C, Veldman-Jones MH, Dorval T, Wilson Z, Jones DR, Lawson D, Odedra R, Maya-Mendoza A, Reimer C, Bartek J, Lau A, O'Connor MJ. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress. Cancer Res 2019; 79:3762-3775. [DOI: 10.1158/0008-5472.can-18-2480] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2018] [Revised: 12/23/2018] [Accepted: 05/20/2019] [Indexed: 11/16/2022]
|
177
|
Verbelen B, Siemes E, Ehnbom A, Räuber C, Rissanen K, Wöll D, Bolm C. From One-Pot NH-Sulfoximidations of Thiophene Derivatives to Dithienylethene-Type Photoswitches. Org Lett 2019; 21:4293-4297. [DOI: 10.1021/acs.orglett.9b01475] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- Bram Verbelen
- Institute of Organic Chemistry, RWTH Aachen University Landoltweg 1, 52074 Aachen, Germany
| | - Eric Siemes
- Institute of Physical Chemistry, RWTH Aachen University Landoltweg 2, 52074 Aachen, Germany
| | - Andreas Ehnbom
- Institute of Organic Chemistry, RWTH Aachen University Landoltweg 1, 52074 Aachen, Germany
- Department of Chemistry, Texas A&M University, P.O. Box 30012, College Station, Texas 77843-3012, United States
| | - Christoph Räuber
- Institute of Organic Chemistry, RWTH Aachen University Landoltweg 1, 52074 Aachen, Germany
| | - Kari Rissanen
- University of Jyvaskyla, Department of Chemistry, P.O. Box 35, 40014, Jyväskylä, Finland
| | - Dominik Wöll
- Institute of Physical Chemistry, RWTH Aachen University Landoltweg 2, 52074 Aachen, Germany
| | - Carsten Bolm
- Institute of Organic Chemistry, RWTH Aachen University Landoltweg 1, 52074 Aachen, Germany
| |
Collapse
|
178
|
Knegtel R, Charrier JD, Durrant S, Davis C, O'Donnell M, Storck P, MacCormick S, Kay D, Pinder J, Virani A, Twin H, Griffiths M, Reaper P, Littlewood P, Young S, Golec J, Pollard J. Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor. J Med Chem 2019; 62:5547-5561. [PMID: 31074988 DOI: 10.1021/acs.jmedchem.9b00426] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The DNA damage response (DDR) is a DNA damage surveillance and repair mechanism that can limit the effectiveness of radiotherapy and DNA-damaging chemotherapy, commonly used treatment modalities in cancer. Two related kinases, ataxia telangiectasia mutated (ATM) and ATM and Rad3-related kinase (ATR), work together as apical proteins in the DDR to maintain genome stability and cell survival in the face of potentially lethal forms of DNA damage. However, compromised ATM signaling is a common characteristic of tumor cells, which places greater reliance on ATR to mediate the DDR. In such circumstances, ATR inhibition has been shown to enhance the toxicity of DNA damaging chemotherapy to many cancer cells in multiple preclinical studies, while healthy tissue with functional ATM can tolerate ATR inhibition. ATR therefore represents a very attractive anticancer target. Herein we describe the discovery of VX-970/M6620, the first ATR inhibitor to enter clinical studies, which is based on a 2-aminopyrazine core first reported by Charrier ( J. Med. Chem. 2011 , 54 , 2320 - 2330 , DOI: 10.1021/jm101488z ).
Collapse
Affiliation(s)
- Ronald Knegtel
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - Jean-Damien Charrier
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - Steven Durrant
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - Chris Davis
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - Michael O'Donnell
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - Pierre Storck
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - Somhairle MacCormick
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - David Kay
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - Joanne Pinder
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - Anisa Virani
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - Heather Twin
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - Matthew Griffiths
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - Philip Reaper
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - Peter Littlewood
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - Steve Young
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - Julian Golec
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| | - John Pollard
- Vertex Pharmaceuticals (Europe) Ltd. , 86-88 Jubilee Avenue, Milton Park , Abingdon , Oxfordshire OX14 4RW , United Kingdom
| |
Collapse
|
179
|
Qi W, Xu X, Wang M, Li X, Wang C, Sun L, Zhao D, Sun L. Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis. Biochem Pharmacol 2019; 164:273-282. [PMID: 31014753 DOI: 10.1016/j.bcp.2019.04.022] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Accepted: 04/19/2019] [Indexed: 12/18/2022]
Abstract
Resistance to standard induction therapy and relapse remain the primary challenges for improving therapeutic effects in acute myeloid leukemia (AML); thus, novel therapeutic strategies are urgently required. Ataxia telangiectasia and Rad3-related protein (ATR) is a key regulator of different types of DNA damage, which is crucial for the maintenance of genomic integrity. The ATR-selective inhibitor VE-822 has proper solubility, potency, and pharmacokinetic properties. In this study, we investigated the anti-leukemic effects of VE-822 alone or combined with Wee1-selective inhibitor AZD1775 in AML cells. Our results showed that VE-822 inhibited AML cell proliferation and induced apoptosis in a dose-dependent manner. AZD1775 significantly promoted VE-822-induced inhibition of AML cell proliferation and led to a decreased number of cells in the G2/M phase. VE-822 and AZD1775 decreased the protein levels of ribonucleotide reductase M1 (RRM1) and M2 (RRM2) subunits, key enzymes in the synthesis of deoxyribonucleoside triphosphate, which increased DNA replication stress. VE-822 combined with AZD1775 synergistically induced AML cell apoptosis and led to replication stress and DNA damage in AML cell lines. Our study demonstrated that AZD1775 synergistically promotes VE-822-induced anti-leukemic activity in AML cell lines and provides support for clinical research on VE-822 in combination with AZD1775 for the treatment of AML patients.
Collapse
Affiliation(s)
- Wenxiu Qi
- Jilin Provincial Key Laboratory of BioMacromolecules of Chinese Medicine, Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, Jilin, China
| | - Xiaohao Xu
- Research Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin, China
| | - Manying Wang
- Research Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin, China
| | - Xiangyan Li
- Jilin Provincial Key Laboratory of BioMacromolecules of Chinese Medicine, Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, Jilin, China
| | - Chaonan Wang
- Jilin Provincial Key Laboratory of BioMacromolecules of Chinese Medicine, Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, Jilin, China
| | - Liping Sun
- Jilin Provincial Key Laboratory of BioMacromolecules of Chinese Medicine, Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, Jilin, China
| | - Daqing Zhao
- Jilin Provincial Key Laboratory of BioMacromolecules of Chinese Medicine, Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, Jilin, China.
| | - Liwei Sun
- Research Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin, China.
| |
Collapse
|
180
|
Li Z, Frings M, Yu H, Bolm C. Organocatalytic Synthesis of Sulfoximidoyl-Containing Carbamates from Sulfoximines and Morita–Baylis–Hillman Carbonates. Org Lett 2019; 21:3119-3122. [DOI: 10.1021/acs.orglett.9b00772] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Zhen Li
- Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany
| | - Marcus Frings
- Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany
| | - Hao Yu
- Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany
| | - Carsten Bolm
- Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany
| |
Collapse
|
181
|
Wiezorek S, Lamers P, Bolm C. Conversion and degradation pathways of sulfoximines. Chem Soc Rev 2019; 48:5408-5423. [DOI: 10.1039/c9cs00483a] [Citation(s) in RCA: 59] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The overview describes laboratory transformations leading to sulfoximine degradations to enable more focussed analyses of potential products and pathways.
Collapse
Affiliation(s)
- Stefan Wiezorek
- Institute of Organic Chemistry
- RWTH Aachen University
- 52074 Aachen
- Germany
| | - Philip Lamers
- Institute of Organic Chemistry
- RWTH Aachen University
- 52074 Aachen
- Germany
| | - Carsten Bolm
- Institute of Organic Chemistry
- RWTH Aachen University
- 52074 Aachen
- Germany
| |
Collapse
|